The Daily Star’s FREE newsletter is spectacular! Sign up today for the best stories straight to your inbox
A hospital worker has died after receiving the AstraZeneca Covid-19 vaccination, the Capital Region of Denmark said.
The worker, who has not been identified, suffered from blood clots and a cerebral haemorrhage less than two weeks after receiving the vaccine.
It is understood the medic is one of two people who suffered complications as a result of the AstraZeneca jab, however, the other individual survived.
The CRD confirmed on Saturday March 20 it received two "serious reports" linked to the vaccine, but did not give any further details, Reuters reported.
Countries including Germany, France and Denmark, put the use of the vaccine on hold earlier on after reports of rare brain blood clots surfaced were connected to the jab.
AstraZeneca, which developed the shot with Oxford University, said it found no evidence of increased risk of blood clots in a review of of 17 million people.
France and Germany reversed the decision to put the jab on hold, but Denmark did not.
The European Union’s watchdog stating on Thursday the benefits outweigh the risks of the coronavirus vaccine.
Ever Cooke, the director of the European Medicines Agency, said a definitive link between blood clots cannot be ruled out.
The EMA said the issue deserves further analysis but said at this stage it is "clear" the benefits in protecting people from Covid death or hospitalisation outweighs the possible risks of blood clotting.
This is a breaking news story and is constantly being updated.
Please refresh the page regularly to get the latest updates.
Reporters working on dailystar.co.uk will be working to source the latest information, reaction, pictures and video related to this story.
You can also follow us on Twitter@DailyStarto get the latest news updates 24 hours a day.
Or download the Daily Star app for flash alerts on the biggest stories of the day.
Why not also subscribe to receive our regular Daily Star news bulletins? You can do this on this page by simply entering your email address above and hitting 'subscribe'.
Source: Read Full Article